Blue Fin Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Blue Fin Capital’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,182	Closed	-$370K	–	116
2015 Q4	$370K	Buy	5,182 +230	+5%	+$15.4K	0.29%	91
2015 Q3	$289K	Sell	4,952 -3,788	-43%	-$323K	0.22%	101
2015 Q2	$790K	Buy	8,740 +220	+3%	+$18.9K	0.57%	55
2015 Q1	$675K	Buy	8,520 +4,780	+128%	+$355K	0.49%	60
2014 Q4	$235K	Buy	+3,740	New	+$219K	0.18%	123

Other funds holding BIB

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RIA

RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Blue Fin Capital's BIB Position: Q1 2016 in Review

Blue Fin Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2016, closing a stake of 5,182 shares — an estimated $370K sold.

Blue Fin Capital first reported a position in BIB in Q4 2014 and held it in 5 quarters. The position peaked at $790K in Q2 2015. 30 funds tracked by Wall St. Rank hold BIB as of Q1 2016.

Blue Fin Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
Blue Fin Capital sold 5,182 ProShares Ultra NASDAQ Biotechnology shares in Q1 2016, an estimated $370K.
Blue Fin Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 5 quarters.
Blue Fin Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $790K in Q2 2015.
30 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2016.

Based on Blue Fin Capital's 13F filing for Q1 2016, filed 14 Apr 2016.